capAI PLC - Fundraise
THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE

capAI plc
(the "Company" and, together with its subsidiaries and subsidiary undertakings, the "Group" or "capAI")
Fundraise
capAI (LSE: CPAI, OTCQB: CPIQF), the applied artificial intelligence ("AI") venture platform, is pleased to announce a conditional fundraise of
Highlights
· Fundraise to raise gross proceeds of
· One warrant to be granted for each new Fundraise Share issued pursuant to the Fundraise, exercisable at
· Professor
· Net proceeds to be utilised to support the continued development of the Group's capMedical vertical, including the Ageotype longevity platform licensed pursuant to the licence and option agreement with R42 Group LLC ("R42") announced by the Company on
· Balance of net proceeds to be applied towards the Group's general working capital requirements
Background
Since the start of 2026, the Group has continued to progress its capital-light venture model across its capMedical and capMedia verticals. In capMedical, the Company executed a licence and option agreement with R42 in respect of Ageotype, an AI-powered longevity and preventative health data platform, representing the Group's first platform within capMedical.
In capMedia, the Company agreed with R42 to extend the licence and option arrangements for Author42, Movie42 and Gamers42, providing additional runway for the continued development and commercialisation of each platform.
The Company's board of directors ("Board") believes the Fundraise will provide the Company with additional resources to continue supporting these initiatives, alongside the Group's general working capital requirements, consistent with its disciplined, capital-efficient strategy.
Details of the Fundraise
The Company has raised gross proceeds of
·
·
In connection with the Fundraise, the Company will grant one Warrant for each Fundraise Share issued, entitling the holder to subscribe for one further new Ordinary Share at an exercise price of
Application has been made for the Fundraise Shares to be admitted to trading on the Main Market ("Admission"). It is expected that Admission will become effective and that dealings in the Fundraise Shares will commence at
The Fundraise is conditional on Admission.
In connection with the Fundraise, the Company will issue new Ordinary Shares with an aggregate value of
Director participation
Professor
This participation demonstrates his continued alignment with Shareholder interests and confidence in the Group's strategy and execution capability.
AlbR acted as the Company's broker in connection with the Placing.
Use of net proceeds
The net proceeds of the Fundraise are intended to be applied by the Company towards the continued development of its capMedical and capMedia platforms, including the Ageotype longevity platform and the Author42, Movie42 and Gamers42 platforms referred to above, as well as working capital.
In addition, the Fundraise supports the Company's capacity to progress a number of further potential opportunities currently under evaluation within these verticals and in certain adjacent sectors, consistent with the disclosure in the Company's announcement of
Total voting rights
Following Admission, the Company's issued share capital will comprise 491,321,950 Ordinary Shares (comprising 426,433,063 Ordinary Shares currently in issue, plus 62,222,221 Fundraise Shares and 2,666,666
In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further updates will be provided as appropriate, in line with the Company's disclosure obligations.
Commenting, Professor
"This Fundraise gives us continued flexibility to build out both our capMedical and capMedia verticals, from advancing Ageotype toward commercial launch to supporting the ongoing development of our media platforms, as well as to evaluate a pipeline of further opportunities. I'm pleased to be able to demonstrate my continued personal commitment to the Company through my participation in the Subscription."
For the purposes of
Enquiries
Company:
capAI plc hello@capaiplc.com
Broker:
AlbR Capital Limited Tel: +44 (0) 207 469 0930
Director's Dealing Notification
The information set out below is provided in accordance with the requirements of Article 19(3) of
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Professor |
||||
|
2 |
Reason for Notification |
|||||
|
a) |
Position/status |
Executive Director, PDMR |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
capAI plc |
||||
|
b) |
LEI |
213800IVPZ932NP24O44 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of nominal value |
||||
|
|
Identification code |
|
||||
|
b) |
Nature of the transaction |
Subscription of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|
||||
|
|
- Aggregated volume |
n/a |
||||
|
|
- Price |
|
||||
|
e) |
Date of the transaction |
|
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
Important Legal Information
The contents of this Announcement have been prepared by, and are the sole responsibility of, the Company.
This Announcement does not constitute, contain or form part of any offer of transferable securities to the public within the meaning attributed to that phrase by section 102B of Financial Services and Markets Act 2000 (as amended).
The Fundraise Shares have not been and will not be registered under the
This Announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this Announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this Announcement applies only as of the date of this Announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this Announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this Announcement is based, unless required to do so by applicable law.
No prospectus, offering memorandum, offering document or admission document has been or will be made available in any jurisdiction in connection with the matters contained or referred to in this Announcement and no such document is required (in accordance with Regulation (EU) No 2017/1129 or the Public Offers and Admissions to Trading Regulations 2024 or the Prospectus Rules: Admission to Trading on a Regulated Market Sourcebook of the FCA) to be published.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE